FOSCAVIR® (FOSCARNET SODIUM)

Clinigen supplies Foscavir® across 43 global markets.

Foscavir® is licensed to treat in many markets:

  • Cytomegalovirus (CMV) retinitis in HIV patients
  • Acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients
  • Cytomegalovirus-Viremia (CMV-Viremia) and CMV disease in patients with hematopoietic stem cell transplantation (HSCT) and with a resistance to or intolerance to ganciclovir

How does it work?

  • Foscavir® selectively inhibits virus-specific DNA polymerase at the pyrophosphate binding site to produce an antiviral effect
  • Since it doesn’t require activation by kinases, it’s active in-vitro against HSV TK deficient mutants and CMV UL97 mutants
  • HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to Foscavir®

Where is Foscavir® licensed?

Australia

Australia

Belgium

Belgium*

France

France

Germany

Germany

Hungary

Hungary*

Israel

Israel

Italy

Italy

Japan - In Japan, Foscavir® is also indicated for the treatment of CMV in hematopoietic stem cell transplant patients

Japan*

Luxembourg

Luxembourg*

Netherlands

Netherlands*

New Zealand

New Zealand

Singapore

Singapore

Spain

Spain

Switzerland

Switzerland

UK

UK

USA

USA

 
* In Belgium, Hungary, Japan, Luxembourg and the Netherlands Foscavir® is also indicated for the treatment of CMV in hematopoietic stem cell transplant patients

 

More Information

Adverse Event Reporting

Medical Enquiries

For general Foscavir® enquiries

Foscavir® Summary of Product Characteristics (SmPC)

Foscavir® Patient Information Leaflet (PIL)

PDF iconExpert Review of Anti-infective Therapy

If you require the SmPC in a different language, please contact our customer services team

Squares